TW201919642A - 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 - Google Patents

19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 Download PDF

Info

Publication number
TW201919642A
TW201919642A TW107132510A TW107132510A TW201919642A TW 201919642 A TW201919642 A TW 201919642A TW 107132510 A TW107132510 A TW 107132510A TW 107132510 A TW107132510 A TW 107132510A TW 201919642 A TW201919642 A TW 201919642A
Authority
TW
Taiwan
Prior art keywords
compound
sleep
individual
administered
effective amount
Prior art date
Application number
TW107132510A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆士 Ｊ 多赫提
史帝芬 傑 凱恩思
杰佛瑞 Ｍ 強納斯
英德吉 考爾
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW201919642A publication Critical patent/TW201919642A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW107132510A 2017-09-14 2018-09-14 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 TW201919642A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762558703P 2017-09-14 2017-09-14
US62/558,703 2017-09-14
US201862624680P 2018-01-31 2018-01-31
US201862624678P 2018-01-31 2018-01-31
US62/624,678 2018-01-31
US62/624,680 2018-01-31
US201862653189P 2018-04-05 2018-04-05
US62/653,189 2018-04-05

Publications (1)

Publication Number Publication Date
TW201919642A true TW201919642A (zh) 2019-06-01

Family

ID=65723895

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107132510A TW201919642A (zh) 2017-09-14 2018-09-14 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
TW111150395A TW202339764A (zh) 2017-09-14 2018-09-14 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111150395A TW202339764A (zh) 2017-09-14 2018-09-14 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法

Country Status (9)

Country Link
US (2) US20220110949A1 (enExample)
EP (2) EP4218767A1 (enExample)
JP (3) JP2020534270A (enExample)
AU (2) AU2018334214A1 (enExample)
CA (1) CA3075872A1 (enExample)
IL (2) IL303083A (enExample)
MX (3) MX2020002889A (enExample)
TW (2) TW201919642A (enExample)
WO (1) WO2019055764A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862076C (en) 2012-01-23 2020-04-21 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
JOP20190022B1 (ar) 2016-08-23 2023-03-28 Sage Therapeutics Inc ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN114761019A (zh) * 2019-12-05 2022-07-15 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362543B (es) * 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
EP4275748A3 (en) * 2014-10-16 2024-01-03 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JOP20190022B1 (ar) * 2016-08-23 2023-03-28 Sage Therapeutics Inc ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري

Also Published As

Publication number Publication date
AU2018334214A1 (en) 2020-03-26
JP2020534270A (ja) 2020-11-26
MX2023010064A (es) 2023-09-06
IL303083A (en) 2023-07-01
JP2023038310A (ja) 2023-03-16
AU2024205601A1 (en) 2024-08-29
WO2019055764A1 (en) 2019-03-21
JP2024107137A (ja) 2024-08-08
TW202339764A (zh) 2023-10-16
MX2020002889A (es) 2020-10-01
EP4218767A1 (en) 2023-08-02
IL273126A (en) 2020-04-30
CA3075872A1 (en) 2019-03-21
MX2023010063A (es) 2023-09-06
EP3681510A1 (en) 2020-07-22
US20220110949A1 (en) 2022-04-14
US20230201224A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
US20230201224A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
Young et al. Sleep in hospitalized medical patients, part 1: factors affecting sleep
AU2015336463B2 (en) Compositions and methods for treating insomnia
TWI795359B (zh) 晝夜節律睡眠障礙之治療方法
JP2025163125A (ja) Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
KR20250129075A (ko) 수유 여성에게 솔리암페톨을 투여하는 방법
US20170151222A1 (en) Snoring treatment
US20250387414A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
HK40096830A (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20220305012A1 (en) Lemborexant for treating sleep issues
RU2844395C2 (ru) Лемборексант для лечения проблем со сном
EP3989976A1 (en) Lemborexant for treating sleep issues
WO2020263331A1 (en) Lemborexant for treating sleep issues
KR20250165616A (ko) 고함량 단일 투여 단위 제형 및 이의 사용 방법
JP2025116005A (ja) 睡眠問題の治療のためのレンボレキサント
AU2024238367A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
JP2025514644A (ja) 痙縮を治療するための化合物及び方法
TW202535357A (zh) 治療更年期及近更年期之方法
TW202539621A (zh) 用於治療巴金森氏症的治療劑
CA2885570C (en) Methods for treating post-traumatic stress disorder
Parkes et al. Disorders of Sleep and Wakefulness
Nath et al. Pediatric Otorhinolaryngology: Diagnosis and Treatment
HK1145282B (en) Treatment of sleep disorders